UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 52

Sortiert nach

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide

CPT: pharmacometrics and systems pharmacology, 2024-03, Vol.13 (3), p.494-503

2024

Link zum Volltext

Verfügbarkeit prüfen

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Molecular metabolism (Germany), 2018-12, Vol.18, p.3-14

2018

Link zum Volltext

Verfügbarkeit prüfen

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Cell metabolism, 2022-09, Vol.34 (9), p.1234-1247.e9

2022

Link zum Volltext

Verfügbarkeit prüfen

Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology

European journal of cancer (1990), 2014-02, Vol.50 (3), p.486-495

2014

Link zum Volltext

Verfügbarkeit prüfen

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists

Diabetes, obesity & metabolism, 2020-10, Vol.22 (10), p.1886-1891

2020

Link zum Volltext

Verfügbarkeit prüfen

Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody

Journal of pharmaceutical sciences, 2010-03, Vol.99 (3), p.1582-1600

2010

Link zum Volltext

Verfügbarkeit prüfen

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

JCI insight, 2020-09, Vol.5 (17)

2020

Link zum Volltext

Verfügbarkeit prüfen

Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009-03, Vol.877 (8), p.837-841

2009

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study Evaluating the Effect of Everolimus on the Pharmacokinetics of Midazolam in Healthy Subjects

Journal of clinical pharmacology, 2013-04, Vol.53 (4), p.444-450

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects

Clinical and translational science, 2021-05, Vol.14 (3), p.1037-1048

2021

Link zum Volltext

Verfügbarkeit prüfen

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Clinical pharmacokinetics, 2021-08, Vol.60 (8), p.1049-1059

2021

Link zum Volltext

Verfügbarkeit prüfen

Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: Application in the detection of colorectal cancer xenografts

mAbs, 2010-01, Vol.2 (1), p.67-72

2010

Link zum Volltext

Verfügbarkeit prüfen

Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study

Clinical therapeutics, 2013-03, Vol.35 (3), p.215-225

2013

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

The Lancet (British edition), 2018-11, Vol.392 (10160), p.2180-2193

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes

Diabetes, obesity & metabolism, 2022-02, Vol.24 (2), p.239-246

2022

Link zum Volltext

Verfügbarkeit prüfen

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

Investigational new drugs, 2014-02, Vol.32 (1), p.123-134

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Diabetes, obesity & metabolism, 2020-06, Vol.22 (6), p.938-946

2020

Link zum Volltext

Verfügbarkeit prüfen

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

The lancet. Diabetes & endocrinology, 2022-06, Vol.10 (6), p.418-429

2022

Link zum Volltext

Verfügbarkeit prüfen

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2023-09, Vol.330 (11), p.1042

2023

Link zum Volltext

Verfügbarkeit prüfen

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

The Lancet (British edition), 2022-11, Vol.400 (10366), p.1869-1881

2022

Link zum Volltext

Verfügbarkeit prüfen

971-P: Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Link zum Volltext

Verfügbarkeit prüfen

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Clinical pharmacokinetics, 2022-07, Vol.61 (7), p.1057-1067

2022

Link zum Volltext

Verfügbarkeit prüfen

Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide

Current medical research and opinion, 2024-04, Vol.40 (4), p.567-574

2024

Link zum Volltext

Verfügbarkeit prüfen

Development and Validation of an Enzyme Linked Immunosorbent Assay for the Quantification of Carcinoembryonic Antigen in Mouse Plasma

Journal of immunoassay & immunochemistry, 2009-10, Vol.30 (4), p.418-427

2009

Link zum Volltext

Verfügbarkeit prüfen

129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(48)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(32)
Science & Technology
(32)
Humans
(22)
Pharmacokinetics
(19)
Diabetes
(18)
Glucagon
(15)
Antidiabetics
(14)
Diabetes Mellitus
(12)
Male
(12)
Diabetes Mellitus, Type 2 - Drug Therapy
(11)
Pharmacology & Pharmacy
(11)
Adult
(10)
Body Weight
(9)
Clinical Trials
(9)
Endocrinology & Metabolism
(9)
Middle Aged
(9)
Weight Control
(9)
Animals
(8)
Dosage
(8)
Drug Dosages
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists

Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues

A Phase I Study Evaluating the Effect of Everolimus on the Pharmacokinetics of Midazolam in Healthy Subjects

Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: Application in the detection of colorectal cancer xenografts

Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

971-P: Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide

Development and Validation of an Enzyme Linked Immunosorbent Assay for the Quantification of Carcinoembryonic Antigen in Mouse Plasma

129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes

Suchergebnisse filtern